MétaCan
Menu
Back to cohort
Record W3013689722 · doi:10.1093/eurheartj/ehaa183

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy

2020· article· en· W3013689722 on OpenAlexaff
Kieran F. Docherty, Pardeep S. Jhund, Silvio E. Inzucchi, Lars Køber, Mikhail Kosiborod, Felipe A. Martínez, Piotr Ponikowski, David L. DeMets, Marc S. Sabatine, Olof Bengtsson, Mikaela Sjöstrand, Anna Maria Langkilde, Akshay S. Desai, Mirta Díez, Jonathan G. Howlett, Tzvetana Katova, Charlotta Ljungman, Eileen O’Meara, Mark C. Petrie, Morten Schou, Subodh Verma, Pham Nguyễn Vinh, Scott D. Solomon, John J.V. McMurray

Bibliographic record

VenueEuropean Heart Journal · 2020
Typearticle
Languageen
FieldMedicine
TopicDiabetes Treatment and Management
Canadian institutionsUniversity of TorontoMontreal Heart InstituteSt. Michael's HospitalUniversité de MontréalUniversity of Calgary
FundersJanssen Research and DevelopmentRelypsaRespicardiaAmerican RegentVifor PharmaUniversity of GlasgowUniversity of OxfordGlaxoSmithKlineIFM TherapeuticsZora BiosciencesMedicines CompanyIntarcia TherapeuticsIronwood Pharmaceuticals, IncorporatedRegeneron PharmaceuticalsSanofi PasteurCelladon CorporationBoston Scientific CorporationEsperion TherapeuticsAlnylam PharmaceuticalsNovo NordiskMyoKardiaDaiichi Sankyo EuropeServierGilead SciencesBritish Heart FoundationEisaiCytokineticsBrigham and Women's HospitalNational Institute of Diabetes and Digestive and Kidney DiseasesSanofiAmgenPfizerAstraZenecaEli Lilly and CompanyBristol-Myers Squibb
KeywordsMedicineDapagliflozinHeart failureInternal medicineCardiologyIntensive care medicineDiabetes mellitusEndocrinology

Abstract

fetched live from OpenAlex

AIMS: In the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced the risk of worsening heart failure (HF) and death in patients with HF and reduced ejection fraction. We examined whether this benefit was consistent in relation to background HF therapy. METHODS AND RESULTS: In this post hoc analysis, we examined the effect of study treatment in the following yes/no subgroups: diuretic, digoxin, mineralocorticoid receptor antagonist (MRA), sacubitril/valsartan, ivabradine, implanted cardioverter-defibrillating (ICD) device, and cardiac resynchronization therapy. We also examined the effect of study drug according to angiotensin-converting enzyme inhibitor/angiotensin receptor blocker dose, beta-blocker (BB) dose, and MRA (≥50% and <50% of target dose). We analysed the primary composite endpoint of cardiovascular death or a worsening HF event. Most randomized patients (n = 4744) were treated with a diuretic (84%), renin-angiotensin system (RAS) blocker (94%), and BB (96%); 52% of those taking a BB and 38% taking a RAS blocker were treated with ≥50% of the recommended dose. Overall, the dapagliflozin vs. placebo hazard ratio (HR) was 0.74 [95% confidence interval (CI) 0.65-0.85] for the primary composite endpoint (P < 0.0001). The effect of dapagliflozin was consistent across all subgroups examined: the HR ranged from 0.57 to 0.86 for primary endpoint, with no significant randomized treatment-by-subgroup interaction. For example, the HR in patients taking a RAS blocker, BB, and MRA at baseline was 0.72 (95% CI 0.61-0.86) compared with 0.77 (95% CI 0.63-0.94) in those not on all three of these treatments (P-interaction 0.64). CONCLUSION: The benefit of dapagliflozin was consistent regardless of background therapy for HF.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.303
Threshold uncertainty score0.537

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.046
GPT teacher head0.295
Teacher spread0.249 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations196
Published2020
Admission routes1
Has abstractyes

Explore more

Same venueEuropean Heart JournalSame topicDiabetes Treatment and ManagementFrench-language works237,207